Innovation

The ClarityDX® system combines machine learning models with clinical and biological data to generate personalized risk scores for each patient. Instead of relying on traditional imaging tests or invasive biopsies, doctors can use these scores to decide whether a patient truly needs further testing. This means fewer unnecessary procedures, less anxiety for patients, and faster, more accurate results for doctors.

What makes this innovation stand out is how it uses technology to solve a real medical challenge. Prostate cancer testing often involves uncertainty; many men undergo painful biopsies only to find out they didn’t need them. ClarityDX® changes that by using AI to analyze data patterns that human doctors might miss, improving the decision-making process.

This innovation supports Sustainable Development Goal (SDG) 3: Good Health and Well-Being, by helping people receive better healthcare through earlier and more precise detection. It also aligns with SDG 9: Industry, Innovation, and Infrastructure, since it brings cutting-edge technology into the medical field. By making diagnostics smarter and more accessible, Nanostics shows how innovation can directly improve human health

Inspiration

The founders of Nanostics were motivated by a clear problem in modern healthcare, diagnostic systems that were too invasive, expensive, and often inaccurate. They saw how existing prostate cancer tests led to stress, over-diagnosis, and unnecessary procedures, and they wanted to create a better solution.

With backgrounds in biomedical research, data science, and entrepreneurship, the founders combined their expertise to design a platform that uses AI to make medical testing faster, safer, and more reliable. Their vision was to bridge the gap between complex clinical data and real-world medical decisions in a way that benefits both doctors and patients.

At its heart, Nanostics was built on the belief that technology can be used to make healthcare more human,not less. The founders’ goal was never just to develop a high-tech product, but to make a meaningful difference by improving the patient experience and empowering medical professionals with better tools. Their story reflects how passion and innovation can come together to create a positive impact in society.

Overall impact

Nanostics’ innovation is not just about prostate cancer. The ClarityDX® platform's adaptable AI model has the potential to transform diagnostics for a wide range of health conditions, including cardiac disease, chronic obstructive pulmonary disease (COPD), and even mental health disorders such as depression. This progression would pave the way for a new era of more accessible medicine.

By integrating complex clinical data with machine learning, the technology can identify subtle patterns that traditional diagnostic tools often overlook. This approach opens new possibilities for early detection, personalized treatment, and preventive medicine that will empower both physicians and patients to make better informed decisions.

Business benefit

The success of Nanostics’ ClarityDX® platform has not only advanced healthcare innovation but also strengthened the company’s position as a leader in AI-driven diagnostics. By developing a solution that eliminates the need for imaging and focuses on data-based precision, Nanostics has differentiated itself in a highly competitive biotech market. This innovation has opened doors to new partnerships across the United States, the Middle East, and other international regions, expanding the company’s global reach.

As Nanostics moves toward FDA approval and U.S. reimbursement, the commercial potential of ClarityDX® continues to grow and enable greater adoption in hospitals and clinics while attracting investors who believe in the future of predictive medicine. Beyond immediate business gains, the adaptability of the platform to detect other diseases ensures long-term sustainability and relevance, which will position Nanostics as a pioneering force at the intersection of technology, healthcare, and global impact.

Social and environmental benefit

Nanostics’ innovation delivers profound social and environmental benefits by reshaping how healthcare systems approach diagnosis and disease prevention. Its emphasis on AI and machine learning reflects a commitment to innovation and sustainable infrastructure (SDG 9), demonstrating how advanced research can generate scalable, cost-effective solutions that strengthen healthcare systems globally. Beyond technology, Nanostics’ partnerships across North America, the Middle East, Europe, and Asia embody global collaboration (SDG 17), bringing equitable healthcare access to diverse populations and fostering international knowledge sharing.

Interview

Catalina Vasquez, Co-founder & COO